Abeona Therapeutics
ABEO
87 hedge funds and large institutions have $230M invested in Abeona Therapeutics in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 16 closing their positions.
214% more call options, than puts
Call options by funds: $2.29M | Put options by funds: $732K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.11% less ownership
Funds ownership: 2.72% → 2.61% (-0.11%)
1% less capital invested
Capital invested by funds: $232M → $230M (-$2.3M)
12% less funds holding
Funds holding: 99 → 87 (-12)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.95M |
| 2 |
Millennium Management
New York
|
+$1.89M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.04M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$787K |
| 5 |
BlackRock
New York
|
+$716K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$5.83M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$2.1M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.93M |
| 4 |
Citigroup
New York
|
-$1.27M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.03M |
ABEO Hedge Fund Activity: Q1 2019 in Review
87 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q1 2019, worth a combined $230M — down 0.99% from $232M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ABEO and 4 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 23 added.
The largest buyer was Vanguard Group, adding an estimated $2.95M. The largest seller was Baker Bros. Advisors, cutting an estimated $5.83M.
- 87 institutional investors held Abeona Therapeutics (ABEO) as of Q1 2019, down from 99 in Q4 2018.
- Funds reported $230M of Abeona Therapeutics stock for Q1 2019, down 0.99% quarter-over-quarter.
- 4 funds opened new Abeona Therapeutics positions in Q1 2019 and 16 closed out, a net change of -12 holders.
- The largest Abeona Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $2.95M added.
- The largest Abeona Therapeutics seller in Q1 2019 was Baker Bros. Advisors, an estimated $5.83M sold.
Based on aggregated 13F filings for Q1 2019.